Online first
Invited Review Article
Published online: 2025-03-27
Innovations in epilepsy treatment: pharmacological strategies and machine learning applications
DOI: 10.5603/pjnns.103446
Pubmed: 40145575
Abstract
Epilepsy remains a significant global health challenge, with a substantial portion of patients experiencing inadequate seizure
control despite existing therapeutic options. This review aimed at exploring recent advances in critical areas that, in the authors’ opinion, hold promise for improving epilepsy treatment outcomes.
Our paper briefly discusses issues related to gene therapy, including recently initiated clinical trials using this technique. Additionally, we explore the utility of machine learning techniques in diagnostics and predicting responses to antiseizure treatment.
Next, we present novel drug delivery routes, such as intranasal and transdermal systems, which provide alternative methods to enhance drug efficacy and minimise side effects. Finally, we briefly characterise new antiseizure medication (ASMs) introduced within the European Union in the last five years, as well as ASMs currently in phase III clinical trials. In summary, this review highlights the potential impact of innovative treatments and technologies on epilepsy management.
Keywords: gene therapymachine learningnew delivery routes for antiseizure medicationsnew antiseizure medications
References
- Keezer MR, Sisodiya SM, Sander JW. Comorbidities of epilepsy: current concepts and future perspectives. Lancet Neurol. 2016; 15(1): 106–115.
- Mula M, Sander JW. Psychosocial aspects of epilepsy: a wider approach. BJPsych Open. 2016; 2(4): 270–274.
- Tang F, Hartz AMS, Bauer B. Drug-Resistant Epilepsy: Multiple Hypotheses, Few Answers. Front Neurol. 2017; 8: 301.
- Bettegazzi B, Cattaneo S, Simonato M, et al. Viral Vector-Based Gene Therapy for Epilepsy: What Does the Future Hold? Mol Diagn Ther. 2024; 28(1): 5–13.
- Zhang Lu, Wang Y. Gene therapy in epilepsy. Biomed Pharmacother. 2021; 143: 112075.
- Kantor B, McCown T, Leone P, et al. Clinical applications involving CNS gene transfer. Adv Genet. 2014; 87: 71–124.
- Baudouin SJ, Giles AR, Pearson N, et al. A novel AAV9-dual microRNA-vector targeting in the hippocampus as a treatment for mesial temporal lobe epilepsy. Mol Ther Methods Clin Dev. 2024; 32(4): 101342.
- Cattaneo S, Bettegazzi B, Crippa L, et al. Gene therapy for epilepsy targeting neuropeptide Y and its Y2 receptor to dentate gyrus granule cells. EMBO Rep. 2024; 25(10): 4387–4409.
- Wykes RC, Lignani G. Gene therapy and editing: Novel potential treatments for neuronal channelopathies. Neuropharmacology. 2018; 132: 108–117.
- Almacellas Barbanoj A, Graham RT, Maffei B, et al. Anti-seizure gene therapy for focal cortical dysplasia. Brain. 2024; 147(2): 542–553.
- Melin E, Nanobashvili A, Avdic U, et al. Disease Modification by Combinatorial Single Vector Gene Therapy: A Preclinical Translational Study in Epilepsy. Mol Ther Methods Clin Dev. 2019; 15: 179–193.
- Agostinho AS, Mietzsch M, Zangrandi L, et al. Dynorphin-based "release on demand" gene therapy for drug-resistant temporal lobe epilepsy. EMBO Mol Med. 2019; 11(10): e9963.
- Kanter-Schlifke I, Fjord-Larsen L, Kusk P, et al. GDNF released from encapsulated cells suppresses seizure activity in the epileptic hippocampus. Exp Neurol. 2009; 216(2): 413–419.
- Niibori Y, Lee SJ, Minassian BA, et al. Sexually Divergent Mortality and Partial Phenotypic Rescue After Gene Therapy in a Mouse Model of Dravet Syndrome. Hum Gene Ther. 2020; 31(5-6): 339–351.
- Colasante G, Qiu Y, Massimino L, et al. In vivo CRISPRa decreases seizures and rescues cognitive deficits in a rodent model of epilepsy. Brain. 2020; 143(3): 891–905.
- Tanenhaus A, Stowe T, Young A, et al. Cell-Selective Adeno-Associated Virus-Mediated Gene Regulation Therapy Rescues Mortality and Seizure Phenotypes in a Dravet Syndrome Mouse Model and Is Well Tolerated in Nonhuman Primates. Hum Gene Ther. 2022; 33(11-12): 579–597.
- Han K, Liu C, Friedman D. Artificial intelligence/machine learning for epilepsy and seizure diagnosis. Epilepsy Behav. 2024; 155: 109736.
- Jing J, Sun H, Kim JA, et al. Development of Expert-Level Automated Detection of Epileptiform Discharges During Electroencephalogram Interpretation. JAMA Neurol. 2020; 77(1): 103–108.
- Kural MA, Jing J, Fürbass F, et al. Accurate identification of EEG recordings with interictal epileptiform discharges using a hybrid approach: Artificial intelligence supervised by human experts. Epilepsia. 2022; 63(5): 1064–1073.
- Fürbass F, Kural MA, Gritsch G, et al. An artificial intelligence-based EEG algorithm for detection of epileptiform EEG discharges: Validation against the diagnostic gold standard. Clin Neurophysiol. 2020; 131(6): 1174–1179.
- Tveit J, Aurlien H, Plis S, et al. Automated Interpretation of Clinical Electroencephalograms Using Artificial Intelligence. JAMA Neurol. 2023; 80(8): 805–812.
- Mansilla D, Tveit J, Aurlien H, et al. Generalizability of electroencephalographic interpretation using artificial intelligence: An external validation study. Epilepsia. 2024; 65(10): 3028–3037.
- Sollee J, Tang L, Igiraneza AB, et al. Artificial intelligence for medical image analysis in epilepsy. Epilepsy Res. 2022; 182: 106861.
- Gill RS, Lee HM, Caldairou B, et al. Multicenter Validation of a Deep Learning Detection Algorithm for Focal Cortical Dysplasia. Neurology. 2021; 97(16): e1571–e1582.
- House PM, Kopelyan M, Braniewska N, et al. Automated detection and segmentation of focal cortical dysplasias (FCDs) with artificial intelligence: Presentation of a novel convolutional neural network and its prospective clinical validation. Epilepsy Res. 2021; 172: 106594.
- Chanra V, Chudzinska A, Braniewska N, et al. Development and prospective clinical validation of a convolutional neural network for automated detection and segmentation of focal cortical dysplasias. Epilepsy Res. 2024; 202: 107357.
- Zheng R, Chen R, Chen C, et al. Automated detection of focal cortical dysplasia based on magnetic resonance imaging and positron emission tomography. Seizure. 2024; 117: 126–132.
- Kaushik M, Mahajan S, Machahary N, et al. Predicting efficacy of antiseizure medication treatment with machine learning algorithms in North Indian population. Epilepsy Res. 2024; 205: 107404.
- Pembegul Yildiz E, Coskun O, Kurekci F, et al. Machine learning models for predicting treatment response in infantile epilepsies. Epilepsy Behav. 2024; 160: 110075.
- Li SP, Lin LC, Yang RC, et al. Predicting the therapeutic response to valproic acid in childhood absence epilepsy through electroencephalogram analysis using machine learning. Epilepsy Behav. 2024; 151: 109647.
- Chmielewska N, Szyndler J. Intranasal administration of antiseizure medications in chronic and emergency treatment: Hopes and challenges. Seizure. 2024; 115: 62–67.
- Detyniecki K, Van Ess PJ, Sequeira DJ, et al. Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters-a randomized, double-blind, placebo-controlled trial. Epilepsia. 2019; 60(9): 1797–1808.
- Wheless JW, Miller I, Hogan RE, et al. DIAZ.001.05 Study Group. Final results from a Phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy. Epilepsia. 2021; 62(10): 2485–2495.
- Shah P, Dubey P, Vyas B, et al. Lamotrigine loaded PLGA nanoparticles intended for direct nose to brain delivery in epilepsy: pharmacokinetic, pharmacodynamic and scintigraphy study. Artif Cells Nanomed Biotechnol. 2021; 49(1): 511–522.
- Bonaccorso A, Gigliobianco MR, Lombardo R, et al. Nanonized carbamazepine for nose-to-brain delivery: pharmaceutical formulation development. Pharm Dev Technol. 2023; 28(2): 248–263.
- Klein P, Aungaroon G, Biton V, et al. Pharmacokinetics and Tolerability of Single-dose Staccato® Alprazolam in Adolescents with Epilepsy and Population PK Analysis to Support Dose Selection in Adolescents (P9-1.002). Neurology. 2024; 102(7_supplement_1).
- French JA, Wechsler R, Gelfand MA, et al. Inhaled alprazolam rapidly suppresses epileptic activity in photosensitive participants. Epilepsia. 2019; 60(8): 1602–1609.
- French J, Biton V, Dave H, et al. A randomized phase 2b efficacy study in patients with seizure episodes with a predictable pattern using Staccato® alprazolam for rapid seizure termination. Epilepsia. 2023; 64(2): 374–385.
- Scheffer I, Hulihan J, Messenheimer J, et al. Cannabidiol Transdermal Gel in Children and Adolescents with Developmental and Epileptic Encephalopathies: An Open-label Clinical Trial (1631). Neurology. 2020; 94(15_supplement).
- Scheffer IE, Hulihan J, Messenheimer J, et al. Safety and Tolerability of Transdermal Cannabidiol Gel in Children With Developmental and Epileptic Encephalopathies: A Nonrandomized Controlled Trial. JAMA Netw Open. 2021; 4(9): e2123930.
- Thiele EA, Bebin EM, Bhathal H, et al. GWPCARE6 Study Group. Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial. JAMA Neurol. 2021; 78(3): 285–292.
- Devinsky O, Cross JH, Laux L, et al. Cannabidiol in Dravet Syndrome Study Group. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med. 2017; 376(21): 2011–2020.
- Miller I, Scheffer IE, Gunning B, et al. GWPCARE2 Study Group. Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial. JAMA Neurol. 2020; 77(5): 613–621.
- Devinsky O, Patel AD, Cross JH, et al. GWPCARE3 Study Group. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. N Engl J Med. 2018; 378(20): 1888–1897.
- Lagae L, Sullivan J, Knupp K, et al. FAiRE DS Study Group. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2019; 394(10216): 2243–2254.
- Nabbout R, Mistry A, Zuberi S, et al. FAiRE, DS Study Group. Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial. JAMA Neurol. 2020; 77(3): 300–308.
- Knupp KG, Scheffer IE, Ceulemans B, et al. Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome: A Randomized Clinical Trial. JAMA Neurol. 2022; 79(6): 554–564.
- Bishop KI, Isquith PK, Gioia GA, et al. Fenfluramine treatment is associated with improvement in everyday executive function in preschool-aged children (<5 years) with Dravet syndrome: A critical period for early neurodevelopment. Epilepsy Behav. 2023; 138: 108994.
- Gil-Nagel A, Cross JH, Devinsky O, et al. Comprehensive scoping review of fenfluramine's role in managing generalized tonic-clonic seizures in developmental and epileptic encephalopathies. Epilepsia. 2024; 65(8): 2186–2199.
- Chung SS, French JA, Kowalski J, et al. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020; 94(22): e2311–e2322.
- Krauss GL, Klein P, Brandt C, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020; 19(1): 38–48.
- Peña-Ceballos J, Moloney PB, Munteanu T, et al. Adjunctive cenobamate in highly active and ultra-refractory focal epilepsy: A "real-world" retrospective study. Epilepsia. 2023; 64(5): 1225–1235.
- Vashi V, Laramy J, Kamin M, et al. Relative Bioavailability of Cenobamate Administered as a Crushed Tablet, Either Orally or via Nasogastric Tube, versus an Intact Whole Tablet. J Clin Pharmacol. 2024; 64(8): 922–931.
- Perucca E, White HS, Bialer M. New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: II. Treatments in Clinical Development. CNS Drugs. 2023; 37(9): 781–795.
- Knight EM, Amin S, Bahi-Buisson N, et al. Marigold Trial Group. Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2022; 21(5): 417–427.
- Kahlig KM, Scott L, Hatch RJ, et al. The novel persistent sodium current inhibitor PRAX-562 has potent anticonvulsant activity with improved protective index relative to standard of care sodium channel blockers. Epilepsia. 2022; 63(3): 697–708.
- Nishi T, Metcalf CS, Fujimoto S, et al. Anticonvulsive properties of soticlestat, a novel cholesterol 24-hydroxylase inhibitor. Epilepsia. 2022; 63(6): 1580–1590.
- Demarest S, Jeste S, Agarwal N, et al. Efficacy, safety, and tolerability of soticlestat as adjunctive therapy for the treatment of seizures in patients with Dup15q syndrome or CDKL5 deficiency disorder in an open-label signal-finding phase II study (ARCADE). Epilepsy Behav. 2023; 142: 109173.
